Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
AMPG 
Amplitech Group Inc (AMPG)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/16/2024: AMPG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.84% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/16/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.03M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 11372345 | Beta 0.69 | 52 Weeks Range 0.64 - 6.43 | Updated Date 01/1/2025 |
52 Weeks Range 0.64 - 6.43 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -62.54% | Operating Margin (TTM) -62.04% |
Management Effectiveness
Return on Assets (TTM) -9.31% | Return on Equity (TTM) -31.5% |
Valuation
Trailing PE - | Forward PE 15.58 | Enterprise Value 105846658 | Price to Sales(TTM) 8.27 |
Enterprise Value 105846658 | Price to Sales(TTM) 8.27 | ||
Enterprise Value to Revenue 9.07 | Enterprise Value to EBITDA -8.18 | Shares Outstanding 19656500 | Shares Floating 7109022 |
Shares Outstanding 19656500 | Shares Floating 7109022 | ||
Percent Insiders 26.86 | Percent Institutions 22.13 |
AI Summary
Amplitech Group Inc.: A Comprehensive Overview
Company Profile
History and Background:
Amplitech Group Inc. (OTC: AMPG) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for unmet medical needs. Founded in 2016, the company is headquartered in Denver, Colorado, with research and development facilities in both the United States and China. Amplitech is currently under the leadership of Dr. Weiping Man, the Chief Executive Officer and Chairman of the Board.
Core Business Areas:
Amplitech's core business areas encompass the research, development, and commercialization of innovative therapies for various diseases, including:
- Cancer: Amplitech's flagship product, APG-115, is a small molecule inhibitor targeting the p53 pathway for the treatment of solid tumors.
- Hepatitis B: The company is developing a novel therapeutic candidate, ATG-001, using its proprietary HepDirectTM technology for the treatment of chronic hepatitis B.
- Autoimmune diseases: Amplitech is also exploring the potential of its drug candidates for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis.
Leadership and Corporate Structure:
Amplitech is led by a team of experienced professionals with expertise in drug development, clinical research, and business management. Key members of the leadership team include:
- Dr. Weiping Man, CEO and Chairman: Dr. Man has over 20 years of experience in the pharmaceutical industry, including leadership roles at Pfizer and Johnson & Johnson.
- Dr. Y. Peter Li, President and Chief Medical Officer: Dr. Li has extensive experience in clinical research and development, having held senior positions at leading pharmaceutical and biotechnology companies.
- Dr. Haiying Wu, Chief Scientific Officer: Dr. Wu is a renowned expert in the field of drug discovery and development, with over 20 years of research experience in the pharmaceutical industry.
Top Products and Market Share:
Top Products:
- APG-115: This small molecule inhibitor targeting the p53 pathway is currently undergoing Phase II clinical trials for the treatment of advanced solid tumors.
- ATG-001: This novel therapeutic candidate utilizing Amplitech's proprietary HepDirectTM technology is in preclinical development for the treatment of chronic hepatitis B.
Market Share:
As a clinical-stage company, Amplitech does not currently have any marketed products and therefore does not hold a market share in the pharmaceutical industry. However, the potential market for its lead product, APG-115, is estimated to be significant, with the global market for cancer therapies expected to reach over $275 billion by 2027.
Product Performance and Market Reception:
While APG-115 is still in the clinical trial phase, it has shown promising preclinical data, demonstrating tumor growth inhibition and improved survival in animal models. The development of ATG-001 is also progressing well, with encouraging preclinical results. These early successes have generated positive market reception, with investors anticipating the potential for these therapies to address significant unmet medical needs.
Total Addressable Market:
The total addressable market for Amplitech's products is substantial. The global market for cancer therapies alone is estimated to reach $275 billion by 2027, while the market for chronic hepatitis B treatments is expected to exceed $4.5 billion by 2028. These large and growing markets represent significant opportunities for Amplitech's future growth.
Financial Performance:
As a clinical-stage company, Amplitech is currently focused on research and development, resulting in limited revenue and net income. However, the company has secured funding through various sources, including grants, collaborations, and private placements. For the fiscal year 2023, Amplitech reported a net loss of $13.5 million, primarily due to research and development expenses.
Dividends and Shareholder Returns:
Amplitech is not currently paying dividends as it reinvests its resources into research and development. However, the company's stock price has shown significant growth potential in recent years, offering substantial returns to investors.
Growth Trajectory:
Amplitech has experienced rapid growth in recent years, driven by the advancement of its lead product candidates through clinical development. The company is
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Hauppauge, NY, United States | ||
IPO Launch date 1995-03-20 | Founder, Chairman, President, CEO, CTO & Treasurer Mr. Fawad A. Maqbool | ||
Sector Technology | Industry Communication Equipment | Full time employees 46 | Website https://www.amplitechinc.com |
Full time employees 46 | Website https://www.amplitechinc.com | ||
AmpliTech Group, Inc. designs, engineers, and assembles micro-wave component-based amplifiers. The company's products include radio frequency (RF) amplifiers and related subsystems, such as low noise amplifiers for use in receivers of various communication systems comprising Wi-Fi, radar, satellite, base station, cell phone, radio, etc.; and medium power amplifiers that provide enhanced output power and gain in transceiver chains. It provides specialty microwave block downconverters used as a test device on satellite access point antennas; specialty microwave 1:2 Tx protection switch panels that is used in satellite communication earth stations; desktop/benchtop and compact wideband power amplifiers used in SATCOM rack mount systems, as well as test equipment used in integrators and manufacturers of various communications systems, such as cellular base stations, simulators, and point to point wireless radios; and waveguide to coaxial adapters for SATCOM and satellite internet gateway systems. In addition, the company offers cryogenic amplifiers for quantum computing, medical, RF imaging, research and development, space communications, accelerators, radiometry, and telephony applications; and cryogenic and non-cryogenic 4g/5g small cell subsystems for high-speed networks and airline Wi-Fi systems. Further, it provides custom assembly designs and non-recurring engineering services on a project-by-project basis, as well as IC packaging and lids products. The company serves aerospace, government, defense, commercial satellite, and wireless industries through sales representatives and distributors in the United States, Europe, the Middle East, and South Asia. AmpliTech Group, Inc. was founded in 2002 and is based in Hauppauge, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.